英格兰急性髓系白血病治疗的社会经济不平等(2015-2022):基于人群的研究
总体49%患者接受ICT,最贫困地区患者接受ICT的可能性比最不贫困地区低6.1%。若所有患者均获得与最不贫困患者相似的ICT可及性,将多247例患者接受ICT;94%的剥夺效应归因于行政集群间变异。
要点
- 尽管实行全民医疗覆盖,英格兰AML强化化疗仍存在社会经济不平等。
- 最贫困地区患者接受强化化疗的可能性比最不贫困地区低6.1%。
- 94%的剥夺效应归因于行政集群间变异,提示机构文化和资源能力等集群层面因素驱动。
核心结论
- 尽管实行全民医疗覆盖,英格兰AML治疗仍存在社会经济不平等,最贫困地区患者接受ICT的可能性更低。
- 该不平等可能由集群层面变异(如机构文化和资源能力)驱动,94%的剥夺效应归因于行政集群间差异。
研究设计与样本
- 通过链接数据库获取Area deprivation status(社会经济剥夺指标)和治疗信息。
- 采用多变量调整的广义回归和混合效应probit回归分析ICT接受率与剥夺程度的关系。
主要发现
- 总体5190例患者(49%)接受了ICT。
- 最贫困地区患者接受ICT的可能性比最不贫困地区患者低6.1%。
- ICT接受率的差异在125个行政集群间存在变异。
- 若所有患者均获得与最不贫困患者相似的ICT可及性,将多247例患者接受ICT。
- 94%的剥夺效应估计归因于行政集群间变异。
关键数值与推荐
- 最贫困地区患者接受ICT的可能性比最不贫困地区低6.1%。
- 94%的剥夺效应归因于行政集群间变异。
- 若消除剥夺相关差异,将多247例患者接受ICT。
临床怎么用
- 临床实践中应关注贫困地区AML患者强化化疗的可及性差异。
- 需针对行政集群层面的机构文化和资源能力进行干预以减少不平等。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The socioeconomic inequality in acute myeloid leukaemia (AML) survival may be driven by differential access to intensive chemotherapy (ICT). We aimed to quantify socioeconomic inequality in the receipt of ICT among patients with AML in England and identify its key drivers. We evaluated 10 495 patients with de novo AML identified in the national cancer registry of England (2015-2022) along with their area-deprivation status, as a measure of socioeconomic inequality, and treatment information based on linkage databases. We related prevalence of the ICT receipt to deprivation with multivariable-adjusted generalised regression and mixed-effects probit regression. Overall, 5190 patients (49%) received ICT. The patients in the most deprived area were 6.1% less likely to receive ICT than those in the least deprived area. The differences in the prevalence measures varied across the 125 administrative clusters of health service units. If all patients had access to ICT similar to the least deprived patients, 247 more patients would receive ICT. Of the deprivation effect, 94% was estimated to be attributable to the variability among administrative clusters. Despite universal healthcare coverage, socioeconomic inequality exists in AML treatment in England. The inequality may be driven by cluster-level variations such as institutional culture and resource capacity.
引用
- Shimizu K, Saito MK, Maringe C, et al. Socioeconomic inequality in treatment of acute myeloid leukaemia (AML) in England, 2015-2022: A population-based study. Br J Haematol. 2026. PMID: 42452790. doi:10.1111/bjh.70695
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。